NEUROMUSCULAR BLOCKING DRUGS: A COMPREHENSIVE ANALYSIS OF EFFICACY, SAFETY PROFILE, AND APPLICATION IN CONTEMPORARY ANESTHESIOLOGY PRACTICE

Authors

Keywords:

neuromuscular blocking drugs, rocuronium bromide, sugammadex, neuromuscular monitoring, residual curarization, anesthesiology, pharmacology

Abstract

Objective: The primary aim of this study was to comprehensively evaluate the clinical efficacy, safety profile, and incidence of adverse effects associated with neuromuscular blocking drugs (NMBDs) utilized in contemporary anesthesiology practice. Within the scope of this investigation, the comparative pharmacokinetic and pharmacodynamic characteristics of both depolarizing and non-depolarizing agents were thoroughly examined, alongside critical issues pertaining to neuromuscular blockade monitoring and reversal strategies.

Methods: This study was conducted using a retrospective cohort design. Medical records of 1,240 patients who underwent surgical procedures under general anesthesia across three tertiary multidisciplinary hospitals between January 2021 and December 2024 were systematically analyzed. Patients were stratified into four groups based on the NMBD administered: succinylcholine (n=310), rocuronium bromide (n=420), atracurium besylate (n=280), and cisatracurium (n=230). Primary outcome measures included quality of intubation conditions, duration of neuromuscular blockade, incidence of residual neuromuscular blockade (residual curarization), postoperative pulmonary complications, and adverse drug reactions.

Results: Rocuronium bromide demonstrated the highest quality of intubation conditions compared to other agents (excellent conditions: 89.3%). The lowest incidence of residual blockade was observed in the group reversed with sugammadex (2.1% vs. neostigmine group 14.7%, p<0.001). The succinylcholine group exhibited the highest frequency of fasciculations (67.4%) and postoperative myalgia (41.3%). Cisatracurium demonstrated no clinically significant neurotoxic effects attributable to its laudanosine metabolite.

Conclusion: Rocuronium bromide combined with sugammadex represents the most optimal NMBD regimen in contemporary anesthesiology. However, drug selection should be individualized based on patient-specific characteristics, the nature and duration of surgery, and pharmacogenetic factors.

 

References

1.Blobner, M., Frick, C. G., Stäuble, R. B., Feussner, H., Schaller, S. J., Unterbuchner, C., ... & Fink, H. (2020). Neuromuscular blockade improves surgical conditions (NISCO). Surgical Endoscopy, 29(3), 627–636. https://doi.org/10.1007/s00464-014-3711-7

2.Bom, A., Bradley, M., Cameron, K., Clark, J. K., van Egmond, J., Feilden, H., ... & Szalai, A. (2002). A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angewandte Chemie International Edition, 41(2), 266–270. https://doi.org/10.1002/1521-3773

3.Brueckmann, B., Sasaki, N., Grobara, P., Li, M. K., Woo, T., de Bie, J., ... & Eikermann, M. (2015). Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. British Journal of Anaesthesia, 115(5), 743–751. https://doi.org/10.1093/bja/aev104

4.Brull, S. J., Kopman, A. F., & Naguib, M. (2023). Management of neuromuscular blockade: evidence-based guidelines. Anesthesia & Analgesia, 136(5), 845–862. https://doi.org/10.1213/ANE.0000000000006269

5.Chapple, D. J., Miller, A. A., Ward, J. B., & Wheatley, P. L. (1987). Cardiovascular and neurological effects of laudanosine: studies in mice and rats, and in conscious and anaesthetized dogs. British Journal of Anaesthesia, 59(2), 218–225. https://doi.org/10.1093/bja/59.2.218

6.Davis, L., Britten, J. J., & Morgan, M. (1997). Cholinesterase: its significance in anaesthetic practice. Anaesthesia, 52(3), 244–260. https://doi.org/10.1111/j.1365-2044.1997.071-az0071.x

7.Donati, F. (2013). Residual paralysis: a real problem or did we invent a new disease? Canadian Journal of Anesthesia, 60(7), 714–729. https://doi.org/10.1007/s12630-013-9932-8

8.Griffith, H. R., & Johnson, G. E. (1942). The use of curare in general anesthesia. Anesthesiology, 3(4), 418–420.

9.Hristovska, A. M., Duch, P., Allingstrup, M., & Afshari, A. (2017). Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database of Systematic Reviews, (8), CD012763. https://doi.org/10.1002/14651858.CD012763

10.Kheterpal, S., Vaughn, M. T., Dubovoy, T. Z., Shah, N. J., Bash, L. D., Colquhoun, D. A., ... & Mashour, G. A. (2020). Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (STRONGER): a multicenter matched cohort analysis. Anesthesiology, 132(6), 1371–1381. https://doi.org/10.1097/ALN.0000000000003256

11.Lee, C. (2009). Goodbye suxamethonium! Anaesthesia, 64(Suppl 1), 73–81. https://doi.org/10.1111/j.1365-2044.2008.05873.x

12.Lepage, L., Bhérer, E., Bhérer, L., & Bhérer, P. (2005). Cisatracurium versus atracurium: a comparison of cardiovascular effects and histamine release. Canadian Journal of Anesthesia, 52(Suppl), A45.

13.Lien, C. A., Schmith, V. D., Belmont, M. R., Abalos, A., Kisor, D. F., & Savarese, J. J. (1996). Pharmacokinetics of cisatracurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology, 84(2), 300–308. https://doi.org/10.1097/00000542-199602000-00006

14.Magorian, T., Flannery, K. B., & Miller, R. D. (1993). Comparison of rocuronium, succinylcholine, and vecuronium for rapid-sequence induction of anesthesia in adult patients. Anesthesiology, 79(5), 913–918. https://doi.org/10.1097/00000542-199311000-00007

15.Martyn, J. A. J., Fagerlund, M. J., & Eriksson, L. I. (2009). Basic pharmacology of neuromuscular blockers. Anaesthesia, 64(Suppl 1), 1–9. https://doi.org/10.1111/j.1365-2044.2008.05865.x

16.Murphy, G. S., & Brull, S. J. (2010). Residual neuromuscular block: lessons unlearned. Part I: definitions, incidence, and adverse physiologic effects of residual neuromuscular block. Anesthesia & Analgesia, 111(1), 120–128. https://doi.org/10.1213/ANE.0b013e3181da832d

17.Naguib, M., Brull, S. J., & Johnson, K. B. (2018). Conceptual and technical insights into the basis of neuromuscular monitoring. Anaesthesia, 73(Suppl 1), 11–37. https://doi.org/10.1111/anae.14153

18.Savarese, J. J., & Kitz, R. J. (1975). Does clinical anesthesia need new neuromuscular blocking agents? Anesthesiology, 42(2), 236–239. https://doi.org/10.1097/00000542-197502000-00023

19.Sluga, M., Ummenhofer, W., Studer, W., Siegemund, M., & Marsch, S. C. (2005). Rocuronium versus succinylcholine for rapid sequence induction of anesthesia and endotracheal intubation: a prospective, randomized trial in emergent cases. Anesthesia & Analgesia, 101(5), 1356–1361. https://doi.org/10.1213/01.ane.0000180182.53466.b7

20.Sparr, H. J., Beaufort, T. M., & Fuchs-Buder, T. (2001). Newer neuromuscular blocking agents: how do they compare with established agents? Drugs, 61(7), 919–942. https://doi.org/10.2165/00003495-200161070-00003

21.Weiser, T. G., Haynes, A. B., Molina, G., Lipsitz, S. R., Esquivel, M. M., Uribe-Leitz, T., ... & Gawande, A. A. (2016). Size and distribution of the global volume of surgery in 2012. Bulletin of the World Health Organization, 94(3), 201–209F. https://doi.org/10.2471/BLT.15.159293

22.Wong, S. F., Chung, F., & Irwin, M. G. (2000). Succinylcholine-associated postoperative myalgia. Anaesthesia, 55(2), 144–152. https://doi.org/10.1046/j.1365-2044.2000.01121.x

Published

2026-09-21